Biologiske modeller i stråleterapi Dag Rune Olsen, The Norwegian Radium Hospital, University of Oslo.

Slides:



Advertisements
Similar presentations
Dose-response Explorer: An Open-source-code Matlab-based tool for modeling treatment outcome as a function of predictive factors Gita Suneja Issam El Naqa,
Advertisements

QUANTITATIVE TUMOUR CONTROL PREDICTIONS FOR THE RADIOTHERAPY OF
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer CCOP Investigators’
Image Reconstruction and Inverse Treatment Planning – Sharpening the Edge – Thomas Bortfeld I.CT Image Reconstruction II.Inverse Treatment Planning.
RADIOTHERAPY ACCIDENT IN COSTA RICA - CAUSE AND PREVENTION OF RADIATION ACCIDENTS IN HOSPITALS Module XIX.
1 A study on the effect of set up errors and organ motion in patients treated with IMRT for prostate cancer S.C. Radioterapia Laboratorio di Fisica Medica.
Predicting the parameters of a prostate IMRT objective function based on dose statistics under fixed parameter settings Renzhi Lu, Richard J. Radke 1,
‘A little to a lot or a lot to a little’ ­ the crucial question to be raised in conformal radiation therapy Professor Dag Rune Olsen, PhD Institute for.
What’s next in IMRT? - Optimizing the Optimization - T. Bortfeld 1, C. Thieke 1,2, K.-H. Küfer 3, H. Trinkaus 3 1 Department of Radiation Oncology, Massachusetts.
Physical optimization criteria Target objective function N t = number of voxels in target D i = dose to voxel i D presc = prescribed dose to target D min.
1 Improved critical structure sparing with biologically based IMRT optimization X.Sharon Qi, Vladimir A. Semenenko and X. Allen Li Department of Radiation.
Direct Consideration of EUD Constraints in IMRT Optimization
Clinical application of TCP ・ NTCP. Lyman JT. Complication probability as assessed from dosevolume histograms. Radiat Res Suppl 1985; 8:S13–S19. Because.
Hypofractionated Radiation Therapy for Early Stage Breast Cancer Patrick J. Gagnon, M.D. Resident, PGY-4 Radiation Medicine, OHSU Providence Hospital Breast.
Time, Dose, and Fractionation
Shannon M MacDonald 1, Salahuddin Ahmad 2, Stefanos Kachris 3, Betty J Vogds 2, Melissa DeRouen 3, Alicia E Gitttleman 3, Keith DeWyngaert 3, Maria T Vlachaki.
Verification Arthur Boyer Stanford University School of Medicine Stanford, California Clinical Aspects Radiobiological Aspects Planning Delivery.
7 Regression & Correlation: Rates Basic Medical Statistics Course October 2010 W. Heemsbergen.
Radiothérapie Hypofractionnée et Cancer de Prostate
Measurement of Dose to Critical Structures Surrounding the Prostate from Intensity-Modulated Radiation Therapy (IMRT) and Three Dimensional Conformal Radiation.
Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):
Data Mining to Aid Beam Angle Selection for IMRT Stuart Price-University of Maryland Bruce Golden- University of Maryland Edward Wasil- American University.
Parameter selection in prostate IMRT Renzhi Lu, Richard J. Radke 1, Andrew Jackson 2 Rensselaer Polytechnic Institute 1,Memorial Sloan-Kettering Cancer.
Computational challenges in RTP treatment planning: setting the stage Joe Deasy, PhD
Predictive models validated by clinical data: new strategies for fractionation Dr. M. Benassi Dr. S. Marzi.
Applications of Geant4 in Proton Radiotherapy at the University of Texas M.D. Anderson Cancer Center Jerimy C. Polf Assistant Professor Department of Radiation.
Factors Influencing the Dose to Rectum During the Treatment of Prostate Cancer with IMRT Nandanuri M.S. Reddy, PhD, Brij M. Sood, MD, and Dattatreyudu.
TREATMENT PLANNING Modelling chemo-hadron therapy Lara Barazzuol | Valencia | 19 June 2009.
Dose-Volume Based Ranking of Incident Beams and its Utility in Facilitating IMRT Beam Placement Jenny Hai, PhD. Department of Radiation Oncology Stanford.
Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.
BREAST MRI IN RADIATION THERAPY PLANNING MARSHA HALEY, M.D. ASSISTANT PROFESSOR UNIVERSITY OF PITTSBURGH CANCER INSTITUTE PITTSBURGH, PENNSYLVANIA, USA.
Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,
Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.
N.B. for a given fraction size
Wang Y 1,2, Damaraju S 1,3,4, Cass CE 1,3,4, Murray D 3,4, Fallone G 3,4, Parliament M 3,4 and Greiner R 1,2 PolyomX Program 1, Department.
Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.
Medical considerations to guide mixed integer formulations of IMRT planning problems from MD to NP to CR Mark Langer, MD Radiation Oncology Indiana University.
Laurie Cuttino MD, Dorin Todor PhD, Douglas Arthur MD, Rohini George, Lynn Pacyna CMD Medical College of Virginia Campus Department of Radiation Oncology.
Electromagnetic redesign of the HYPERcollar applicator: towards improved deep local head-and-neck hyperthermia *P. Togni, Z. Rijnen, W.C.M. Numan, R.F.
A Tumour Control Probability based approach to the development of Plan Acceptance Criteria for Planning Target Volume in Intensity Modulated Radiation.
Mathematical Modelling within Radiotherapy: The 5 R’s of Radiotherapy and the LQ model. Helen McAneney 1 and SFC O’Rourke 1,2 1 School Mathematics and.
Michael Brada Torino 6 March 2015 Perspectives in lung cancer Stereotactic ablative radiation therapy (SABR) in patients with inoperable NSCLC.
Cancer.orgPredict Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung.
Karolina Kokurewicz Supervisors: Dino Jaroszynski, Giuseppe Schettino
Flair development for the MC TPS Wioletta Kozłowska CERN / Medical University of Vienna.
Reducing excess imaging dose to cancer patients receiving radiotherapy Adam Schwertner, Justin Guan, Xiaofei Ying, Darrin Pelland, Ann Morris, Ryan Flynn.
TEMPLATE DESIGN © Optimization of Cancer Radiation Treatment Schedules Jiafen Gong* and Thomas Hillen Department of Mathematical.
 Multidisciplinary Effort › Surgery › Radiation › Systemic Rx (chemo, “drugs”)
The use of Radiotherapy in Cancer.. What is radiotherapy? The treatment of cancer with ionising radiation is called Radiotherapy or Radiation Oncology.
UNIVERSAL SURVIVAL CURVE AND SINGLE FRACTION EQUIVALENT DOSE: USEFUL TOOLS IN UNDERSTANDING POTENCY OF ABLATIVE RADIOTHERAPY CLINT PARK, M.D. M.S., LECH.
The Effects of Small Field Dosimetry on the Biological Models Used In Evaluating IMRT Dose Distributions Gene Cardarelli,PhD, MPH.
Does my bum look big in this? Audit of rectal volumes and AP diameter in planning scans for radical prostate radiotherapy Tse V, Lorimer CFK, Parker R,
Department of Clinical Radiotherapy, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK R4 한재준 1.
Radiobiological concepts for treatment planning of schemes that combines external beam radiotherapy and systemic targeted radiotherapy (CIERT) Carlos Calderón.
Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,
Basic Clinical Radiobiology Ch. 5 Dose–response relationships in radiotherapy SØREN M. BENTZEN.
RBE: open issues and next challenges Francesco Tommasino Workshop: la radiobiologia in INFN Trento, Maggio 2016.
Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate.
Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards  Charles S. Mayo, PhD, John.
Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Correlation between urinary dose and delayed radiation cystitis after 78Gy intensity- modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up.
Figure 1 Concept of the therapeutic index
Figure 6 Double opposed-field irradiation of an idealized geometry
Improved outcome of treating locally advanced lung cancer with the use of Lattice Radiotherapy (LRT): A case report  Beatriz E. Amendola, Naipy C. Perez,
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Advances in radiation oncology
The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and.
Jesse Conterato, BA&Sc. RSNA 2016
Proton Beam Therapy for Liver Cancer is Well Tolerated: Outcomes from the Proton Collaborative Group REG Trial Michael Chuong, M.D.1,2, Smith Apisarnthanarx,
Presentation transcript:

Biologiske modeller i stråleterapi Dag Rune Olsen, The Norwegian Radium Hospital, University of Oslo

Biological models Physical dose Biological response or Clinical outcome f (var, param) InputModelOutput

Biological models Empirical models of clinical data Biophysical models of the underlying biological mechanisms

Biological models The EUD – a semi-biological approach: “The concept of equivalent uniform dose (EUD) assumes that any two dose distributions are equivalent if they cause the same radiobiological effect.” The idea based on a law by Weber-Fechner- Stevens:R  S a A. Niemierko, Med Pys. 24:1323-4, 1997

Biological models EUD: EUD=  v i D i a i where D i is the dose of a voxel element ‘i’ and v i is the corresponding volume fraction of the element; a is a parameter. Q. WU et al. Int. Radiat. Oncol. Biol. Phys. 52:224-35, 2002

Biological models EUD: The corresponding equivalent uniform dose – based on the DVH. a of tumours is often large, negative a of serial organs is large, positive a of parallel organs is small, positive Q. WU et al. Int. Radiat. Oncol. Biol. Phys. 52:224-35, 2002 A typical DVH of normal tissue

Biological models Calculation of the response probability Normal tissue complication probability NTCP Tumour controle probability TCP

Biological models Normal tissue complication probability t NTCP=1/  2    e (-x 2 /2) dx -  NTCP=1/(1+[D 50% /D] k ) G. Kutcher et al. Int J Radiat. Oncol. Biol. Phys. 21: , A. Niemierko et al.Radiother. Oncol. 20: , H. Honore et al. Radiother Oncol. 65:9-16, 2002.

Biological models Normal tissue complication probability and the volume effect A Jackson et al. Int J Radiat Oncol Biol Phys. 31:883-91, JD Fenwick et al. Int J Radiat Oncol Biol Phys. 49:473-80, t NTCP=1/  2    e (-x 2 /2) dx -  t=D-D(v)/m  D(v) D(v)=D  V -n

Biological models Sensitivity analysis : NTCP of Grade 1–3 rectal bleeding damage, together with the steepest and shallowest sigmoid curves (dotted lines) which adequately fit the data. JD Fenwick et al. Int J Radiat. Oncol. Biol. Phys. 49:473-80, 2001.

Biological models Normal tissue complication probability Biophysical models assume that the function of an organ is related to the inactivation probability of the organs functional sub units - FSU – and their functional organization.

E. Dale et al. Int J Radiat Oncol Biol Phys.43:385-91, 1999 Olsen DR et al. Br J Radiol. 67: , E. Yorke Radiother Oncol. 26:226-37, Biological models NTCP=1-  [ n ](1-p) y x p n-y y p FSU inactivation probability yk+n-N Ntotal number of FSUs k/Nfraction of FSU that needs to be intact nirradiated FSUs y n Normal tissue complication probability

Biological models S.L.S. Kwa et al. Radiother. Oncol. 48:61- 69, Response probability calculations require: 3D dose matrix of VOI Reduction to an effective dose Appropriate set of parameter values Reliable model

Biological models Volume Dose DVH reduction algorithm: D eff (v)=  (D i  V i -n ) i Lyman et al. IJROBP 1989 Kutcher et al. IJROBP 1989 Emami et al. IJROBP 1991 Burman et al. IJROBP 1991

Biological models Dose NTCP TD 50% (v) 50% 100% Mean = D 50% (v) SD = m·D 50% TD distribution t NTCP=1/  2    e (-x 2 /2) dx -  t=D-D(v)/m  D(v) D(v)=D  V -n Lyman et al. IJROBP 1989 Kutcher et al. IJROBP 1989 Emami et al. IJROBP 1991 Burman et al. IJROBP 1991

Biological models Probability of radiation induced liver desease (RILD) by NTCP modelling for patients with hepatocellular carcinoma (HCC) treated with three- dimensional conformal radiotherapy (3D-CRT). Fits from the literature and the new fits from 68 patients for the Lyman NTCP model displaying 5% and 50% iso-NTCP curves of the corresponding effective volume and dose. J. C.-H. Cheng et al. Int J Radiat. Oncol. Biol. Phys. 54:156-62, 2002

Biological models Tumour controle probability TCP TCP= exp(-n o  SF) SF=exp[-(  d+  d 2 )] exp([d-TCD50]/k) 1+ exp([d-TCD50]/k) TCP curves that result from the set of parameters chosen for prostate cancer (  = 0.29 Gy -1;  = 10 Gy;  V = 10 7 cells/cm 3. A Nahum, S. Webb, Med.Phys. 40:1735-8, 1995 H. Suit et al. Radiother. Oncol. 25:251-60, TCP=

Cost functions Cost functions are mathematical models that simulate the process of clinical assessment and judgement. Cost functions produce a single figure of merit for tumour control and acute and late sequela, and is as such a composit score of the treatment plan

Cost functions Utility function U=  w i  NTCP  w o  (1-TCP) where w are weight factors, NTCP i is the probability of a given toxicity (end-point) of an organ i, and TCP is the tumour control probability. w i is not always a fixed parameter but rather a function, e.g. may w=  for the spinal cord, i.e. w=0 for d 50 Gt. i

Cost functions P + -concept Introduced by Wambersie in 1988 as ‘Uncomplicated Tumour Control’ and refined by Brahme: P + =P B -P B  I where P B is the tumour control probability and P I is the normal tissue complication probability.

Cost functions P + -concept When no correlation between the to probabilities exist: P + =P B -P B  P I When full correlation between the to probabilities exist: P + =P B - P I

Cost functions P + -concept Plot of P + demonstrate what dose is optimal with respect to tumour control without late toxicity P + can be used to rank plans Fig. Problems: how to deal with non-fatal complications and ‘softer’ end-points ?

Automatic ranking Automated ranking and scoring of plans can be performed using artificial neural networks Correlation between network and clinical scoring T.R. Willoughby et al. Int J Radiat. Oncol. Biol. Phys. 34: , 1996

Models in treatment plan evaluation …is larger in practice than in theory !” John Wilkes “The difference between theory and practice…